Payment overview · 2025
General Payments
$82.54
4 reported records · 4 companies
Healthcare provider profile · identity verified
Bethani K Rose, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PIKEVILLE, KY · NPI 1326367715
Verified facts
What the public records show
CMS Open Payments records show Bethani K Rose, D.O. received $82.54 in general payments during 2025 across 4 reported records.
Dexcom, Inc. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.20 | 37.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.97 | 24.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.93 | 20.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.44 | 17.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $82.54 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 117 |
| Lisinopril | Lisinopril | 280 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 66 |
| Omeprazole | Omeprazole | 175 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 136 | 46 |
| Metformin Hcl | Metformin Hcl | 130 | 40 |
| Gabapentin | Gabapentin | 127 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 40 |
| Sertraline Hcl | Sertraline Hcl | 122 | 34 |
| Famotidine | Famotidine | 117 | 40 |
| Potassium Chloride | Potassium Chloride | 117 | 45 |
| Losartan Potassium | Losartan Potassium | 111 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 33 |
| Montelukast Sodium | Montelukast Sodium | 95 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 32 |
| Furosemide | Furosemide | 91 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 26 |
| Trazodone Hcl | Trazodone Hcl | 84 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 27 |
| Clonazepam | Clonazepam | 77 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 27 |
| Mounjaro | Tirzepatide | 70 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 20 |
| Simvastatin | Simvastatin | 67 | 18 |
| Buspirone Hcl | Buspirone Hcl | 64 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 25 |
| Celecoxib | Celecoxib | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 13 |
| Carvedilol | Carvedilol | 55 | 11 |
| Tramadol Hcl | Tramadol Hcl | 52 | suppressed |
| Ozempic | Semaglutide | 51 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 18 |
| Atenolol | Atenolol | 47 | 14 |
| Meloxicam | Meloxicam | 47 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 17 |
| Lorazepam | Lorazepam | 46 | 11 |
| Diazepam | Diazepam | 45 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 15 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Bupropion Xl | Bupropion Hcl | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Estradiol | Estradiol | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $82.54 · 4 records | Dexcom, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error